MB
MBX.US MBX Biosciences, Inc. Common Stock
- Market cap
- USD 2.64B
- P/E
- -
- P/B
- 5.87x
- ROE
- -34.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is MBX.US undervalued?
Graham numberThe Graham number of MBX Biosciences, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MBX Biosciences, Inc. Common Stock fundamental analysis
No fundamental analysis for MBX Biosciences, Inc. Common Stock yet.
MBX Biosciences, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MBX Biosciences, Inc. Common Stock
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) recep…
Full company profileMBX Biosciences, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
MBX Biosciences, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -56.0K | -157K | -244K | -248K | - |
| Operating Income | -25.2M | -35.3M | -68.2M | -98.1M | -179M |
| EBITDA | -25.7M | -32.4M | -61.7M | -86.7M | -169M |
| Net Income | -26.1M | -32.6M | -61.9M | -87.0M | -164M |
| EPS | -0.82 | -1.02 | -1.85 | -2.38 | -3.38 |
| Balance Sheet | |||||
| Total Assets | 45.1M | 84.2M | 269M | 385M | 501M |
| Total Liabilities | 87.7M | 157M | 11.1M | 15.9M | 27.7M |
| Shareholders' Equity | -42.6M | -72.5M | 257M | 369M | 473M |
| Cash & Short-term Investments | 42.5M | 80.7M | 262M | 374M | 482M |
| Total Debt | 461K | 324K | 171K | 596K | 3.29M |
| Cash Flow | |||||
| Operating Cash Flow | -23.1M | -32.0M | -54.7M | -79.9M | -104M |
| Capital Expenditure | 441K | 129K | 874K | 1.93M | 3.37M |
| Free Cash Flow | -23.6M | -32.1M | -55.6M | -81.9M | -107M |
| Ratios | |||||
| ROE | - | - | -24.1% | -23.6% | -34.7% |
| ROA | -58.0% | -38.7% | -23.1% | -22.6% | -32.8% |
| Debt to Equity | - | - | 0.00x | 0.00x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
MBX Biosciences, Inc. Common Stock dividends
MBX Biosciences, Inc. Common Stock has not paid dividends in the last 4 fiscal years.
Who owns MBX Biosciences, Inc. Common Stock
- Insiders 3.22%
- Institutions 96.78%
- Public & others 0.00%
- Shares outstanding 49.7M
- Free float 32.5M
Top funds holding MBX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Polar Capital Biotech S Inc | 1.52M | 3.07% | 0.00% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 1.06M | 2.13% | -7.05% | Sep 2026 |
| Eventide Healthcare & Life Sciences I | 873K | 1.76% | -1.85% | Jun 2026 |
| Fidelity Advisor Biotechnology I | 818K | 1.65% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 784K | 1.58% | 0.00% | Oct 2026 |
| Fidelity Select Health Care | 680K | 1.37% | 0.00% | Aug 2026 |
| Fidelity Stock Selector Small Cap | 675K | 1.36% | +6.07% | Aug 2026 |
| T. Rowe Price Health Sciences | 444K | 0.90% | 0.00% | Sep 2026 |
| Fidelity Small Cap Growth | 416K | 0.84% | 0.00% | Aug 2026 |
| Strategic Advisers Fidelity US TtlStk | 353K | 0.71% | +52.09% | Sep 2026 |
| Fidelity Advisor Health Care I | 345K | 0.70% | +5.18% | Sep 2026 |
| Fidelity Series Small Cap Opps | 340K | 0.69% | -6.79% | Aug 2026 |
| Fidelity Small Cap Index | 340K | 0.68% | +0.14% | Aug 2026 |
| BlackRock Health Sciences Opps Inv A | 333K | 0.67% | 0.00% | Sep 2026 |
| Fidelity | 321K | 0.65% | 0.00% | Aug 2026 |
| Heptagon Driehaus US Micro Cap Eq C$ Acc | 297K | 0.60% | 0.00% | Sep 2026 |
| Candriam Eqs L Biotech C USD Cap | 294K | 0.59% | 0.00% | Apr 2026 |
| iShares Russell 2000 Growth ETF | 291K | 0.59% | -0.38% | Oct 2026 |
| Fidelity Select Biotechnology | 241K | 0.49% | 0.00% | Aug 2026 |
| iShares Biotechnology ETF | 238K | 0.48% | -0.19% | Oct 2026 |
Top institutions holding MBX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 6.65M | 13.40% | 0.00% | Jun 2026 |
| FMR Inc | 5.32M | 10.72% | +81.25% | Jun 2026 |
| Wellington Management Company LLP | 4.98M | 10.03% | +55.95% | Jun 2026 |
| NEA Management Company, LLC | 3.61M | 7.28% | 0.00% | Jun 2026 |
| Orbimed Advisors LLC | 3.43M | 6.91% | -5.75% | Jun 2026 |
| BlackRock Inc | 3.32M | 6.70% | +13.00% | Jun 2026 |
| Paradigm Biocapital Advisors LP | 2.51M | 5.05% | 0.00% | Jun 2026 |
| NVP Associates LLC | 2.14M | 4.30% | 0.00% | Sep 2026 |
| Deep Track Capital, LP | 1.73M | 3.49% | -37.17% | Jun 2026 |
| Polar Capital Holdings PLC | 1.61M | 3.24% | -0.84% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.48M | 2.98% | -0.01% | Jun 2026 |
| Aaron Wealth Advisors LLC | 1.17M | 2.35% | -0.03% | Jun 2026 |
| Driehaus Capital Management LLC | 1.06M | 2.13% | +3.77% | Jun 2026 |
| Kynam Capital Management, LP | 935K | 1.88% | 0.00% | Jun 2026 |
| Woodline Partners LP | 900K | 1.81% | +0.00% | Jun 2026 |
| Eventide Asset Management, LLC | 873K | 1.76% | -1.85% | Jun 2026 |
| State Street Corp | 864K | 1.74% | +9.81% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 815K | 1.64% | -20.82% | Jun 2026 |
| Parkman Healthcare Partners LLC | 800K | 1.61% | +0.02% | Jun 2026 |
| Geode Capital Management, LLC | 773K | 1.56% | +15.32% | Jun 2026 |
MBX Biosciences, Inc. Common Stock company profile
- Company name
- MBX Biosciences, Inc. Common Stock
- Ticker
- MBX.US
- Exchange
- USA Stocks
- Listed since
- Sep 13, 2024
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 63
- Fiscal year end
- December
- Address
- 11711 North Meridian Street, Carmel, IN, United States, 46032
- Phone
- 317 659 0200
- Website
- mbxbio.com
About MBX Biosciences, Inc. Common Stock
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
MBX Biosciences, Inc. Common Stock management
10- Mr. Steven L. HoerterExecutive Chairperson, CEO & President · born 1971
- Dr. Salomon Azoulay M.D.Chief Medical Officer · born 1958
- Mr. John W. Smither CPAChief Financial Officer · born 1953
- Mr. Pete De SpainSenior Vice President of Investor Relations & Corporate Communications
- Mr. Jeffrey Held J.D.Chief Legal Officer · born 1969
- Ms. Michelle GrahamChief Human Resources Officer · born 1967
- Dr. Michael A. Dorato DABT, Ph.D.Sr. Vice President of Discovery & Non-Clinical Development
- Dr. Chatan Charan Ph.D.Senior VP of Pharmaceutical Development & Chemistry, Manufacturing and Controls
- Mr. Mark HopeChief Regulatory & Quality Officer
- Dr. Andreas Moraitis M.D.Senior Vice President of Clinical Development